PHE - Corporate - Acute Drug Harms Surveillance and Early Warning System in UK Emergency Departments

Public Health England (PHE) is seeking to commission an external partner with an existing system and / or capability to deliver an opioid and new psychoactive substances (NPS) clinical harms surveillance programme. The programme will: - rapidly detect any incident involving synthetic opioids in the heroin or cocaine markets; - monitor the emergence of a synthetic opioid market as seen in North America; - identify health harms associated with toxicity from emerging/new NPS, such as synthetic cannabinoids.